Department of Pediatrics, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
Department of Radiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
Respir Med. 2020 Dec;175:106209. doi: 10.1016/j.rmed.2020.106209. Epub 2020 Nov 2.
The prevalence of macrolide-resistant Mycoplasma pneumoniae (MP) pneumonia has been rapidly increased. MP pneumonia is a risk factor for the development of post-infectious bronchiolitis obliterans (PIBO). The aim of the present study was to identify the risk factors for the development of PIBO after MP pneumonia in the era of increasing macrolide resistance of MP.
This retrospective study enrolled 150 children with a mean age of 6.0 years admitted to the hospital due to MP pneumonia between May 2019 and February 2020 at a tertiary hospital. The clinical, radiologic, and laboratory data were obtained using retrospective chart review.
Eighteen children (12%) were diagnosed with PIBO after MP pneumonia. PIBO was diagnosed after a mean duration of 100.0 days (range, 6-268 days) from symptom onset. The respiratory virus co-infection (adjusted odds ratio [aOR], 4.069; 95% confidence interval [95% CI], 1.224-13.523), adenovirus co-infection (aOR, 5.607; 95% CI, 1.801-17.454), longer duration between symptom onset and admission (aOR, 1.150; 95% CI, 1.020-1.298), higher levels of serum lactate dehydrogenase (LDH) at the time of admission (aOR, 1.001; 95% CI, 1.000-1.003), and poor response to stepwise treatment increased the risk for development of PIBO after MP pneumonia. However, macrolide resistance of MP was not associated with development of PIBO after MP pneumonia.
The present study suggests that respiratory virus co-infection, including adenovirus, poor response to the treatment of MP pneumonia, and higher levels of serum LDH, but not macrolide resistance of MP, are risk factors of PIBO after MP pneumonia.
大环内酯类耐药肺炎支原体(MP)肺炎的患病率迅速上升。MP 肺炎是发生感染后细支气管炎闭塞性(PIBO)的危险因素。本研究的目的是在 MP 大环内酯类耐药率上升的时代,确定 MP 肺炎后发生 PIBO 的危险因素。
这项回顾性研究纳入了 2019 年 5 月至 2020 年 2 月在一家三级医院因 MP 肺炎住院的 150 名平均年龄为 6.0 岁的儿童。通过回顾性病历回顾获取临床、影像学和实验室数据。
18 名儿童(12%)在 MP 肺炎后被诊断为 PIBO。从症状出现到诊断 PIBO 的平均时间为 100.0 天(范围为 6-268 天)。呼吸道病毒合并感染(调整优势比 [aOR],4.069;95%置信区间 [95%CI],1.224-13.523)、腺病毒合并感染(aOR,5.607;95%CI,1.801-17.454)、症状出现至入院时间较长(aOR,1.150;95%CI,1.020-1.298)、入院时血清乳酸脱氢酶(LDH)水平较高(aOR,1.001;95%CI,1.000-1.003)以及对阶梯式治疗的反应不佳会增加 MP 肺炎后发生 PIBO 的风险。然而,MP 对大环内酯类药物的耐药性与 MP 肺炎后发生 PIBO 无关。
本研究表明,呼吸道病毒合并感染(包括腺病毒)、MP 肺炎治疗反应不佳以及血清 LDH 水平较高,而不是 MP 对大环内酯类药物的耐药性,是 MP 肺炎后发生 PIBO 的危险因素。